Novartis debuts €40M viral vector plant in Slovenia, part of €3.5B investment push in the country
Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 million ($41.2 million) viral vector facility in Mengeš, Slovenia. The new site brings the drugmaker’s total investment in the …